ERBB2 and breast carcinoma: TILs have been shown to be associated with improved outcomes in HER2-positive breast cancer patients treated with adjuvant chemotherapy in the BIG 02–98 trial7 as well as an abbreviated course of trastuzumab and adjuvant chemotherapy in the FinHER trial8.